The most important precaution is to identify the filler before treating the same anatomical area. If a patient has received a permanent, non-biodegradable, or unknown soft-tissue filler—such as liquid silicone or an acrylic hydrogel—CO₂ fractional laser resurfacing in that area should generally be avoided. Thermal treatment can provoke severe, unpredictable inflammation, including a delayed “burst granuloma,” and may cause substantial tissue damage.
Do not treat over or near an injection site unless the filler’s composition, location, and degradability are clearly documented. Unknown or permanent fillers are a strong reason to defer or avoid energy-based treatment in that anatomical region.
Establish Whether Laser Treatment Is Appropriate
Obtain a complete filler history
Ask specifically about:
- The product name and manufacturer
- The date and anatomical injection sites
- Whether the filler was intended to be temporary or permanent
- The treating clinician or clinic
- Any previous swelling, nodules, redness, pain, or inflammatory reactions
Patients may not know the exact product. In that situation, request treatment records, product stickers, invoices, or documentation from the original injector whenever possible.
Treat unknown filler composition as a safety concern
A patient’s description—such as “silicone-like,” “gel,” or “permanent filler”—is not sufficient to establish safety. If the material cannot be definitively identified, practitioners should not assume that it is biodegradable or compatible with ablative laser treatment.
Avoid CO₂ laser treatment in the affected anatomical area until the material has been reliably characterized and the risks have been assessed by an appropriately qualified clinician.
Identify the precise treatment zone
The relevant question is not simply whether the patient has ever had filler. Determine whether the proposed laser field overlaps the injected area or is close enough to expose it to significant thermal energy.
Document the filler sites on the treatment plan and photographs. If the filler location is uncertain, that uncertainty should be treated conservatively rather than resolved by proceeding with treatment.
Understand Why Permanent Fillers Are High Risk
Thermal energy can trigger an inflammatory response
CO₂ fractional resurfacing creates controlled thermal injury in the skin. Permanent or poorly characterized materials may respond unpredictably to this heat and to the resulting inflammatory cascade.
Possible consequences include intense swelling, persistent inflammation, nodules, granulomatous reactions, and tissue injury. A flare-up may also make it difficult to distinguish a laser complication from an infection or a filler-related disorder.
“Permanent” does not mean clinically inactive
A non-biodegradable filler can remain present in tissue for a prolonged period. Even if the patient has tolerated it for years, that history does not establish that it will remain clinically quiet after aggressive resurfacing.
The absence of previous filler complications is reassuring but does not remove the risk associated with applying ablative energy over an unknown or permanent material.
Biodegradable fillers still require documentation
A known, temporary filler is not automatically risk-free. The practitioner should still confirm the product, injection location, treatment timing, and whether any current swelling, nodules, tenderness, or inflammation is present.
If there is active or unexplained filler-related inflammation, postpone resurfacing and investigate the problem before exposing the area to additional thermal injury.
Complete the Broader Pre-Treatment Screening
Check for active skin disease or infection
Do not proceed through active herpes simplex, bacterial infection, eczema, psoriasis, or other significant inflammatory skin disease in the treatment area. Conditions associated with a Koebner phenomenon, such as vitiligo or psoriasis, require particular caution.
Patients with a history of herpes simplex may require oral antiviral prophylaxis beginning before treatment and continuing afterward according to the clinician’s protocol.
Assess scarring and healing risks
Review any history of:
- Keloid or hypertrophic scarring
- Delayed wound healing
- Abnormal pigmentation
- Connective-tissue or autoimmune skin disease
- Prior facial irradiation
- Recent surgery or tissue undermining
Recent oral isotretinoin use and other factors that may impair re-epithelialization should also be reviewed before an ablative procedure.
Review medications and cosmetic preparation
Review anticoagulants, antiplatelet agents, photosensitizing drugs, topical retinoids, and oral retinoids. Medication changes must be supervised medically rather than directed casually by the aesthetic practitioner.
The patient should avoid tanning and ultraviolet exposure before treatment. For patients prone to melasma or post-inflammatory hyperpigmentation—particularly those with darker or Asian skin types—the clinician may recommend a pre-treatment pigment-control regimen.
Use Conservative Treatment Planning
Consider a test spot
A localized test spot should be considered, particularly when the patient has a higher risk of pigmentary change, scarring, or an uncertain tissue response. The supplementary guidance recommends performing testing at least two weeks before full treatment when appropriate.
A test spot does not prove that treatment over permanent filler is safe. It can help assess skin responsiveness, but it should not replace identification of the injected material.
Watch for excessive thermal response
Immediate white or gray discoloration can indicate excessive thermal impact. This should prompt reassessment of parameters such as fluence, density, pulse characteristics, and pulse overlap before proceeding.
Unexpected tissue behavior is a reason to stop and reassess—not simply to continue with lower settings without understanding the cause.
Avoid aggressive assumptions about energy settings
Use the least aggressive treatment plan that can reasonably address the patient’s indication. The presence of filler, uncertain tissue characteristics, darker skin phototype, prior scarring, or treatment on the neck should all favor additional caution.
Neck skin, in particular, has a higher risk of scarring and prolonged erythema and generally requires more conservative settings than facial skin.
Coordinate the Timing of Other Procedures
Do not laser recently undermined skin
If the patient has recently undergone a facelift or another procedure that compromises local blood supply, delay resurfacing until tissue vascularization has recovered. The supplementary guidance identifies an interval of approximately three months after a surgical lift before laser resurfacing.
Treating recently undermined skin can create a serious risk of full-thickness necrosis. This concern is separate from filler safety but should be included in the same procedural risk assessment.
Postpone treatment when the diagnosis is unclear
Unexplained nodules, recurrent swelling, persistent redness, pain, or changes around a filler site require evaluation before resurfacing. Laser treatment should not be used to conceal or empirically treat a problem that has not been diagnosed.
Understanding the Trade-offs
Treating despite uncertainty can expand the problem
Proceeding over an unknown filler may preserve the planned cosmetic schedule, but a severe inflammatory reaction can lead to prolonged treatment, scarring, pigmentary change, and diagnostic confusion.
Avoiding the area or deferring treatment is less convenient, but it is usually the more defensible choice when the material cannot be identified.
A test spot is useful but limited
Test patches help evaluate skin response and optimize parameters. They cannot reliably exclude delayed filler-related inflammation or establish that a permanent filler will tolerate broader resurfacing.
They should therefore be viewed as an additional safeguard, not a clearance test for unknown materials.
A known temporary filler is not an automatic clearance
Even when a filler is documented as biodegradable, treatment still requires assessment of the injection site, timing, current tissue condition, skin type, and other contraindications. The risk profile is lower than with an unknown permanent filler, but it is not zero.
Maintain Procedural and Aftercare Safety
Control laser-generated aerosols
Ablative CO₂ treatment generates smoke and aerosolized biological material. Use a dedicated smoke evacuator, visible laser warning signage, and restricted access during treatment.
These controls protect staff and patients and should be part of the clinic’s standard operating procedure.
Prepare patients for healing
Patients should receive written instructions covering gentle cleansing, ointment use, edema control, activity restrictions, and strict sun protection. The initial healing period commonly requires frequent wound care and avoidance of sweating, friction, and ultraviolet exposure.
Persistent redness, increasing pain, worsening swelling, drainage, fever, or new nodules should prompt clinical review rather than routine reassurance.
Document the decision
Record the filler history, evidence used to identify the product, injection locations, examination findings, contraindication screening, test-spot results if performed, treatment parameters, and consent discussion.
When filler information is incomplete, document the uncertainty and the rationale for avoiding treatment in that area.
How to Apply This to Your Project
The safest workflow is to make filler identification a formal prerequisite, not an informal question during the consultation.
- If your primary focus is patient safety: Defer CO₂ treatment over any area containing a permanent or unknown filler until the material and location are definitively established.
- If your primary focus is treatment planning: Map prior injection sites, assess current tissue condition, and use conservative parameters with a suitable test spot when clinically appropriate.
- If your primary focus is complication prevention: Screen for infection, inflammatory disease, scarring risk, medications, isotretinoin exposure, pigmentary risk, and recent surgery before scheduling treatment.
- If your primary focus is clinical governance: Use documented consent, standardized laser safety controls, written aftercare, and a clear escalation pathway for delayed swelling or nodules.
When filler history is uncertain, the safest treatment decision is to pause, investigate, and avoid ablative energy in the affected area until the risk is understood.
Summary Table:
| Precaution | Key Action | Rationale |
|---|---|---|
| Identify filler | Ask product name, manufacturer, date, sites, type (temporary/permanent), and any reactions | Unknown or permanent fillers risk severe inflammation |
| Treat unknown as high risk | Avoid CO2 over area unless filler is clearly identified | Thermal energy can cause burst granuloma or tissue damage |
| Map injection sites | Document exact locations and compare with laser treatment area | Overlap can lead to complications |
| Check for active issues | Postpone if swelling, nodules, or inflammation present | Reduces risk of worsening |
| Consider test spot | Perform at least 2 weeks prior, if appropriate | Assess skin response but not filler safety |
| Use conservative settings | Lower fluence, density, etc., especially on neck or darker skin | Minimizes thermal injury |
| Screen for other risks | Review infection, scarring, medications, isotretinoin, recent surgery | Comprehensive safety |
| Control smoke and aftercare | Use smoke evacuator, provide written instructions | Standard procedural safety |
Master safe laser protocols with BELIS's advanced aesthetic devices, designed for professional clinics and premium salons. Our portfolio includes CO2 fractional lasers and other systems, supported by training and documentation to help you deliver exceptional results while prioritizing patient safety. Contact our team today to explore how BELIS can elevate your practice. Get in touch now to discuss your needs and discover exclusive benefits for clinics and distributors.
Related Products
People Also Ask
- What is the technical principle behind CO2 Laser Fractional micro-perforations? Master Scar Revision Mechanics
- Why are professional laser systems, such as CO2 fractional or Erbium lasers, more effective for deep wrinkle reduction and dermal remodeling than topical anti-aging ingredients like retinoids, vitamin C, or peptides? Discover the targeted power of fractional lasers.
- What role does fractional CO2 laser equipment play in the treatment of SUI? Non-Surgical Stress Urinary Incontinence Care
- What is the rationale for a double-pass technique with fractional CO2 lasers? Maximize Deep Collagen Remodeling
- What is the purpose of manually extracting large cysts before CO2 fractional laser? Optimize Eyelid Milia En Plaque Care
